Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Medtech
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds and APIs
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
Multimedia
Blog
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Breadcrumb
Home
Vantage
Pharmaceutical Companies
Immunosyn
October 01, 2009
Human Genome, OncoGenex stand out small caps so far in 2009
July 03, 2009
Generics still doing well amongst small-caps in first half
October 30, 2008
Big Pharma hunting for bargains have plenty of choice
March 31, 2008
Financial woes could deflate Immunosyn
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
September 22, 2022
ESMO 2022 eBook
September 01, 2022
PD(L)anner – September 2022
Editor's Picks
July 27, 2022
Aids 2022 preview – Gilead shoots for an HIV cure
July 21, 2022
Private equity gets serious about drug development
July 18, 2022
Unpacking Royalty Pharma
July 19, 2022
No plain sailing for Novartis’s PD-1 plan
July 26, 2022
Move over Aduhelm, it’s tofersen’s turn
